;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Permira seeks $4 billion for sale of contract drugmaker Cambrex, FT reports

Finance

Permira seeks $4 billion for sale of contract drugmaker Cambrex, FT reports

Published by Global Banking and Finance Review

Posted on September 6, 2025

Featured image for article about Finance

(Reuters) -British private equity firm Permira has put its contract drugmaker Cambrex up for sale, targeting a valuation of as much as $4 billion, the Financial Times reported on Saturday citing people familiar with the matter.

Reuters could not immediately verify the report.

(Reporting by Anusha Shah in Bengaluru; Editing by Aidan Lewis)

More from Finance

Explore more articles in the Finance category

Jimmy Lai remains beacon of Hong Kong press freedom, say ex-colleagues awaiting his sentencing

US eases sanctions on three Belarus potash companies after prisoner release

EU's Kallas: China is increasingly weaponizing economic ties for political gains

Romania's government survives no-confidence vote over judicial pensions

Russian opposition party that wants Ukraine ceasefire vows to keep campaigning despite crackdown

Oaktree-backed firm unveils $1.2 billion Amsterdam 'hyperscale' data centre project

Sterling holds steady ahead of BoE decision this week

Russian court rules in favour of Rusal in $1.32 billion lawsuit against Rio Tinto

Ukraine strikes Russian oil infrastructure in Caspian Sea for third time, source says

Exclusive-France and Italy aligned on need to delay final Mercosur vote, say sources

Germany deepens commitment to Ukraine's defence in 10-point plan

Doctors in England to strike after they reject government's offer

View All Finance Posts